To the full analysis
Buyback calculator for NeoGenomics
NeoGenomics stock: key metrics
NEONeoGenomics had an operating margin of −9.1% and a return on invested capital (ROIC) of −4.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 57.4% | 2.2% | −2.0% |
| 2007 | 52.0% | −27.3% | −29.4% |
| 2008 | 53.3% | −4.4% | −6.9% |
| 2009 | 51.6% | −5.9% | −7.6% |
| 2010 | 45.9% | −8.6% | −9.6% |
| 2011 | 44.7% | −0.9% | −2.7% |
| 2012 | 44.8% | 2.0% | 0.1% |
| 2013 | 0.1% | 4.8% | 3.1% |
| 2014 | 46.8% | 2.5% | 1.3% |
| 2015 | 43.8% | −5.6% | −2.5% |
| 2016 | 45.2% | 1.1% | −2.5% |
| 2017 | 42.4% | 1.2% | −0.2% |
| 2018 | 46.0% | 3.6% | 1.0% |
| 2019 | 48.1% | 3.2% | 2.0% |
| 2020 | 41.8% | −3.1% | 0.9% |
| 2021 | 38.6% | −24.5% | −1.7% |
| 2022 | 36.9% | −30.9% | −28.3% |
| 2023 | 41.3% | −18.2% | −14.9% |
| 2024 | 43.9% | −13.9% | −11.9% |
| 2025 | 38.8% | −9.1% | −14.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | 23.4% | −4.2% |
| 2007 | −100.0% | −88.1% | −51.8% |
| 2008 | −92.1% | −18.8% | −19.0% |
| 2009 | −39.7% | −23.2% | −17.3% |
| 2010 | −100.0% | −28.6% | −24.2% |
| 2011 | −20.0% | −3.1% | −5.9% |
| 2012 | 0.7% | 7.3% | 0.2% |
| 2013 | 9.4% | 12.2% | 5.1% |
| 2014 | 1.9% | 6.2% | 1.4% |
| 2015 | −1.1% | −2.8% | −0.7% |
| 2016 | −3.3% | 0.7% | −1.8% |
| 2017 | −0.2% | 0.8% | −0.1% |
| 2018 | 0.8% | 1.9% | 0.5% |
| 2019 | 1.6% | 2.9% | 1.1% |
| 2020 | 0.6% | −2.0% | 0.4% |
| 2021 | −0.8% | −10.3% | −0.4% |
| 2022 | −14.5% | −10.5% | −8.3% |
| 2023 | −9.3% | −7.4% | −5.2% |
| 2024 | −8.7% | −6.4% | −4.8% |
| 2025 | −12.9% | −4.6% | −7.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2020)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.